News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche (JOBS) Antiviral Meets Main Goal in Late-Stage Study
February 17, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Feb 13 (Reuters) - Swiss drugmaker Roche Holding AG said its already approved antiviral Valcyte, met the main goal of a late-stage study.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
Roche
MORE ON THIS TOPIC
Pancreatic cancer
Verastem deprioritizes pancreatic cancer work after ‘decent, but not great’ data shadowed by Revolution
June 18, 2026
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Biogen makes up to $1B immuno play with RayThera takeover
June 18, 2026
·
2 min read
·
Tristan Manalac
Deals
Jazz strikes new chord with AbCellera in T cell engager pact that could top $2.4B
June 17, 2026
·
2 min read
·
Gabrielle Masson
Huntington’s disease
UniQure plans Q3 submission for Huntington’s gene therapy after FDA reverses course—again
June 17, 2026
·
4 min read
·
Heather McKenzie
